PTEN and myotubularin phosphatases: From 3-phosphoinositide dephosphorylation to disease

Trends in Cell Biology

Volumn 12, Issue 12, 2002, Pages 579-585

  Wishart, Matthew J ^a,b   Dixon, Jack E ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHOSPHOINOSITIDE; INOSITOL; MYOTUBULARIN; PHOSPHATASE; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL; PROTEIN TYROSINE PHOSPHATASE; PTEN PROTEIN, HUMAN;

CANCER; CANCER INHIBITION; CHROMOSOME; HUMAN; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SEQUENCE HOMOLOGY; CHEMISTRY; GENERAL ASPECTS OF DISEASE; METABOLISM; PHOSPHORYLATION;

DISEASE; HUMANS; PHOSPHATIDYLINOSITOLS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN-TYROSINE-PHOSPHATASE; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0036899518     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8924(02)02412-1     Document Type: Review

References (42)

1. Vanhaesebroeck B., et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70:2001;535-602.
2. Cullen P.J., et al. Modular phosphoinositide-binding domains - their role in signalling and membrane trafficking. Curr. Biol. 11:2001;R882-R893.
3. Brazil D.P., Hemmings B.A. Ten years of protein kinase B signaling: a hard Akt to follow. Trends Biochem. Sci. 26:2001;657-664.
4. Li J., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
5. Steck P.A., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:1997;356-362.
6. Waite K.A., Eng C. Protean PTEN: form and function. Am. J. Hum. Genet. 70:2002;829-844.
7. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273:1998;13375-13378.
8. Maehama T., et al. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu. Rev. Biochem. 70:2001;247-279.
9. Di Cristofano A., et al. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19:1998;348-355.
10. Suzuki A., et al. Male infertility, impaired spermatogenesis, and azoospermia in mice deficient for the pseudophosphatase Curr. Biol. 22:1998;1169-1178.
11. Morrison S.J. Pten-uating neural growth. Nat. Med. 8:2002;16-18.
12. Marino S., et al. PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development. 129:2002;3513-3522.
13. Huang H., et al. PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development. Development. 126:1999;5365-5372.
14. Goberdhan D.C., et al. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13:1999;3244-3258.
15. Ogg S., Ruvkun G. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol. Cell. 2:1998;887-893.
16. Mihaylova V.T., et al. The PTEN tumor suppressor homolog in Caenorhabditis elegans regulates longevity and dauer formation in an insulin receptor-like signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 96:1999;7427-7432.
17. Butler M., et al. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes. 51:2002;1028-1034.
18. Iijima M., Devreotes P. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell. 109:2002;599-610.
19. Funamoto S., et al. Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. Cell. 109:2002;611-623.
20. Lee J.O., et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 99:1999;323-334.
21. Wu X., et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl. Acad. Sci. U. S. A. 97:2000;4233-4238.
22. Wu Y., et al. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J. Biol. Chem. 275:2000;21477-21485.
23. Vazquez F., et al. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 276:2001;48627-48630.
24. Birle D., et al. Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. J. Immunol. 169:2002;286-291.
25. Koul D., et al. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene. 21:2002;2357-2364.
26. Stambolic V., et al. Regulation of PTEN transcription by p53. Mol. Cell. 8:2001;317-325.
27. Virolle T., et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat. Cell Biol. 3:2001;1124-1128.
28. Patel L., et al. Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr. Biol. 11:2001;764-768.
29. Mayo L.D., et al. Male infertility, impaired spermatogenesis, and azoospermia in mice deficient for the pseudophosphatase. J. Biol. Chem. 15:2002;5484-5489.
30. Walker S.M., et al. TPIP: a novel phosphoinositide 3-phosphatase. Biochem. J. 360:2001;277-283.
31. Wishart M.J., et al. PTEN and myotubularin phosphoinositide phosphatases: bringing bioinformatics to the lab bench. Curr. Opin. Cell Biol. 13:2001;172-181.
32. Laporte J., et al. The myotubularin family: from genetic disease to phosphoinositide metabolism. Trends Genet. 17:2001;221-228.
33. Taylor G.S., et al. Inaugural article: myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8910-8915.
34. Kim S.A., et al. Myotubularin and MTMR2, phosphatidylinositol 3-phosphatases mutated in myotubular myopathy and type 4B Charcot-Marie-Tooth disease. J. Biol. Chem. 277:2002;4526-4531.
35. Walker D.M., et al. Characterization of MTMR3, an inositol lipid 3-phosphatase with novel substrate specificity. Curr. Biol. 11:2001;1600-1605.
36. Laporte J., et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat. Genet. 13:1996;175-182.
37. Sutton I.J., et al. Limb girdle and facial weakness in female carriers of X-linked myotubular myopathy mutations. Neurology. 57:2001;900-902.
38. Bolino A., et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat. Genet. 25:2000;17-19.
39. Firestein R., et al. Male infertility, impaired spermatogenesis, and azoospermia in mice deficient for the pseudophosphatase Sbf1. J. Clin. Invest. 109:2002;1165-1172.
40. Nandurkar H.H., et al. Characterization of an adapter subunit to a phosphatidylinositol (3)P 3-phosphatase: identification of a myotubularin-related protein lacking catalytic activity. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9499-9504.
41. Laporte J., et al. Functional redundancy in the myotubularin family. Biochem. Biophys. Res. Commun. 291:2002;305-312.
42. Crackower M.A., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 110:2002;737-749.